4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
Janus Henderson Group plc amended a Schedule 13G to report beneficial ownership of 5,247,151 shares of 4D Molecular Therapeutics, Inc., representing 10.3% of the common stock as disclosed. The filing states the Asset Managers exercise shared voting and dispositive power over these shares and disclaim rights to dividends or sale proceeds tied to the Managed Portfolios. The amendment is signed on 04/07/2026 and the cover lists 03/31/2026 in the header.
4D Molecular Therapeutics, Inc. announced a leadership change in its finance function. On March 25, 2026, the Board appointed Kristian Humer as the company’s Principal Accounting Officer, effective immediately. He will hold this role in addition to serving as Chief Financial Officer and Principal Financial Officer.
Humer succeeds Ashoo Gupta in the Principal Accounting Officer role; Gupta remains Vice President, Finance and Controller. The filing highlights Humer’s prior experience as CFO at Foghorn Therapeutics and Viridian Therapeutics and his earlier senior investment banking roles at Citigroup focused on healthcare.
4D Molecular Therapeutics granted Chief Executive Officer David Kirn a stock option covering 750,000 shares of common stock. The option has an exercise price of $9.88 per share and expires on March 24, 2036.
The award vests over four years, with 1/48 of the shares vesting monthly starting on March 25, 2026, so long as he continues as a service provider. Following this grant, the filing shows 750,000 derivative securities (options) held directly by Kirn.
4D Molecular Therapeutics reported a stock option grant to Chief Legal Officer Scott Bizily. The award covers 217,000 options for common stock at an exercise price of $9.88 per share and expires on March 24, 2036.
The options vest in equal monthly installments over four years, with 1/48th of the underlying shares vesting on each monthly anniversary of March 25, 2026, so long as Bizily remains a service provider. This is a compensation-related equity grant, not an open-market share purchase or sale.
4D Molecular Therapeutics, Inc. reported that officer Christopher Paul Simms received a grant of stock options covering 219,000 shares of common stock. The options have an exercise price of $9.88 per share and expire on March 24, 2036.
According to the terms, 1/48 of the underlying shares will vest each month starting on March 25, 2026, so long as Simms remains a service provider, with full vesting on the fourth anniversary of that date. Following this grant, he holds options for 219,000 shares directly.
4D Molecular Therapeutics Inc Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led certain Vanguard subsidiaries to report separately.
4D Molecular Therapeutics VP Ashoo Gupta reported routine equity compensation activity. On March 20, 2026, Gupta exercised restricted stock units (RSUs) into 1,086 shares of common stock at a conversion price of $0.00 per share.
On the same date, 390 common shares were sold at $8.61 per share in an automatic “sell-to-cover” transaction to satisfy tax withholding obligations, as described in the footnotes, rather than a discretionary trade. Following these transactions, Gupta directly held 47,055 common shares, plus RSU awards that continue to vest beginning on June 20, 2025 in scheduled quarterly installments while serving as a company service provider.
4D Molecular Therapeutics describes a late-stage gene therapy pipeline focused on retinal and lung diseases. Lead candidate 4D-150, for wet age-related macular degeneration and diabetic macular edema, is in global Phase 3 trials with RMAT and PRIME designations and strong early data on reducing anti-VEGF injection burden.
The company is also advancing 4D-710 for cystic fibrosis lung disease, showing durable CFTR expression and early clinical activity in the AEROW Phase 1/2 trial, with Phase 2 dosing selected. As of June 30, 2025, non-affiliate equity was valued at $166,461,070, and as of March 16, 2026, 51,051,487 common shares were outstanding, with an additional 16,935,665 shares issuable upon exercise of pre-funded warrants.
4D Molecular Therapeutics reported full year 2025 results and highlighted major partnering and financing activities that support its late-stage gene therapy pipeline. Collaboration and license revenue rose to $85.2 million, mainly from an upfront payment under the Otsuka partnership, while net loss narrowed to $140.1 million from $160.9 million in 2024. Research and development expenses increased to $195.7 million, reflecting advancement of the 4D-150 Phase 3 wet AMD program and other trials. Cash, cash equivalents and marketable securities were $514.0 million as of December 31, 2025, which the company expects will fund its operating plan into the second half of 2028. The company also completed an additional $118 million in equity financings and reported positive interim data and upcoming milestones for 4D-150 in retinal diseases and 4D-710 for cystic fibrosis lung disease.
Novo Holdings A/S reported beneficial ownership of 3,650,737 shares of 4D Molecular Therapeutics common stock, representing 6.4% of the outstanding class as of the event date. Novo Holdings has sole power to vote and dispose of these shares, with no shared voting or dispositive power.
The filing states that the position was not acquired and is not held for the purpose of changing or influencing control of the company, indicating a passive investment intent under the Schedule 13G framework.